IOVA - Iovance Biotherapeutics to Present at Upcoming Conferences and Events | Benzinga
SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events:
- TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Fireside Chat: May 28, 2024 at 3:00 p.m. ET
Virtual
- Iovance ASCO Investor/Analyst Event
Presentation and Key Opinion Leader Panel Discussion: May 31, 2024 at 7:15 p.m. ET
Chicago, IL and Virtual
- Jefferies Global Healthcare Conference
Fireside Chat: June 6, 2024 at 9:30 a.m. ET
New York, NY
- Goldman Sachs Global Healthcare Conference
Fireside Chat: June 10, 2024 at 2:40 p.m. ET
Miami, FL
- Iovance 2024 Annual Meeting
June 11, 2024 at 11:00 a.m. ET
Virtual
The live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance's Amtagvi™ is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
Amtagvi™ and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Forward-Looking Statements
Certain matters discussed in this press release are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Without limiting the foregoing, we may, in some cases, use terms such as ...